The Antiresorptive Effects of a Single Dose of Zoledronate Persist for Two Years: A Randomized, Placebo-Controlled Trial in Osteopenic Postmenopausal Women
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Context: Annual iv administration of 5 mg zoledronate decreases fracture risk. The optimal dosing interval of 5 mg zoledronate is not known. Objective: Our objective was to determine the duration of antiresorptive action of a single 5-mg dose of iv zoledronate. Design, Setting, and Participants: We conducted a double-blind, randomized, placebo-controlled trial over 2 yr at an academic research center, in a volunteer sample of 50 postmenopausal women with osteopenia. Intervention: Intervention included 5 mg zoledronate. Main Outcome Measures: Biochemical markers of bone turnover and bone mineral density of the lumbar spine, proximal femur, and total body. Results: Compared with placebo, zoledronate treatment decreased mean levels of each of four markers of bone turnover by at least 38% (range 38–45%) for the duration of the study (P < 0.0001 for each marker). After 2 yr, bone mineral density was higher in the zoledronate group than the placebo group by an average of 5.7% (95% confidence interval = 4.0–7.4) at the lumbar spine, 3.9% (2.2–5.7) at the proximal femur, and 1.7% (0.8–2.5) at the total body (P < 0.0001 for each skeletal site). Between-groups differences in markers of bone turnover and bone mineral density were similar at 12 and 24 months. Mild secondary hyperparathyroidism was present throughout the study in the zoledronate group. Conclusion: The antiresorptive effects of a single 5-mg dose of zoledronate are sustained for at least 2 yr. The magnitudes of the effects on markers of bone turnover and bone mineral density are comparable at 12 and 24 months. Administration of zoledronate at intervals of up to 2 yr may be associated with antifracture efficacy; clinical trials to investigate this possibility are justified.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis
Black, D. M., Delmas, P. D., Eastell, R., Reid, I. R., Boonen, S., Cauley, J. A., Cosman, F., Lakatos, P., Leung, P. C., Man, Z., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067312 · Cited by 2,986 · cited 7×
“(1) in an osteoporotic population, it is of interest to compare the findings of these studies.”
BackgroundResultSelf-citationZoledronic Acid and Clinical Fractures and Mortality after Hip Fracture
Lyles, K. W., Colón-Emeric, C. S., Magaziner, J. S., Adachi, J. D., Pieper, C. F., Mautalen, C., Hyldstrup, L., Recknor, C., Nordsletten, L., Moore, K. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa074941 · Cited by 2,003 · cited 4×
“Duration of Action of Zoledronate J Clin Endocrinol Metab, February 2009, 94(2):538–544”
BackgroundInfluentialPrevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin
Plotkin, L. I., Weinstein, R. S., Parfitt, A. M., Roberson, P. K., Manolagas, S. C., & Bellido, T. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6800 · Cited by 890 · cited 1×
“A further possibility is that zoledronate may itself prolong osteoblast and osteocyte survival, as has been demonstrated for other bisphosphonates in vitro (18).”
Background
Research works printed but not linked: 14
- Reid, 2002, Intravenous zoledronic acid in postmenopausal women with low bone mineral density., N Engl J Med, 346, 653, 10.1056/NEJMoa011807 · DOI · Paper page
- Devogelaer, 2007, Zoledronic acid efficacy and safety over five years in postmenopausal osteoporosis., Osteoporos Int, 18, 1211, 10.1007/s00198-007-0367-3 · DOI
- Bolland, 2008, Effects of intravenous zoledronate on bone turnover and BMD persist for at least 24 months., J Bone Miner Res, 23, 1304, 10.1359/jbmr.080312 · DOI
- Thiébaud, 1997, Effects of ibandronate i.v, bolus injection in healthy men and postmenopausal women. J Bone Miner Res, 12, S343
- Borba, 2007, Bone turnover 18 months after a single intravenous dose of zoledronic acid., Int J Clin Pract, 61, 1058, 10.1111/j.1742-1241.2007.01392.x · doi:10.1111/j.1742-1241.2007.01392.x
- Brown, 2007, Prolonged efficacy of a single dose of the bisphosphonate zoledronic acid., Clin Cancer Res, 13, 5406, 10.1158/1078-0432.CCR-07-0247 · DOI
- Recker, 2008, Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure., J Bone Miner Res, 23, 6, 10.1359/jbmr.070906 · DOI · Paper page
- Chavassieux, 1997, Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis., J Clin Invest, 100, 1475, 10.1172/JCI119668 · DOI · Paper page
- Eriksen, 2002, Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis., Bone, 31, 620, 10.1016/S8756-3282(02)00869-4 · DOI · Paper page
- Recker, 2004, Histomorphometric evaluation of daily and intermittent oral ibandronate in women with postmenopausal osteoporosis: results from the BONE study., Osteoporos Int, 15, 231, 10.1007/s00198-003-1530-0 · DOI
- Iida-Klein, 2007, Effects of cyclic vs. daily treatment with human parathyroid hormone (1–34) on murine bone structure and cellular activity., Bone, 40, 391, 10.1016/j.bone.2006.09.010 · DOI
- Kim, 2003, Trabecular bone response to mechanical and parathyroid hormone stimulation: the role of mechanical microenvironment., J Bone Miner Res, 18, 2116, 10.1359/jbmr.2003.18.12.2116 · DOI
- Rubin, 2002, The anabolic effects of parathyroid hormone., Osteoporos Int, 13, 267, 10.1007/s001980200026 · DOI
- Cramer, 2007, A systematic review of persistence and compliance with bisphosphonates for osteoporosis., Osteoporos Int, 18, 1023, 10.1007/s00198-006-0322-8 · DOI · Paper page
Cited by
Black, D. M., Reid, I. R., Boonen, S., Bucci-Rechtweg, C., Cauley, J. A., Cosman, F., Cummings, S. R., Hue, T. F., Lippuner, K., Lakatos, P., et al. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1494 · Cited by 700
Self-citationAdverse effects of bisphosphonates: Implications for osteoporosis management
Kennel, K. A., & Drake, M. T. (2009) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)60752-0 · Cited by 496
“The duration of suppression parallels bisphosphonate potency for osteoclast inhibition, such that administration of a single 5-mg dose of the potent IV bisphosphonate zoledronic acid to postmenopausal women leads to continued suppression of biochemical markers of bone resorption 2 years after drug administration.(4) A…”
BackgroundCalcium intake and bone mineral density: systematic review and meta-analysis
Tai, V., Leung, W., Grey, A., Reid, I. R., & Bolland, M. J. (2015) · BMJ · doi:10.1136/bmj.h4183 · Cited by 408
Self-citationAllen, M. R., & Burr, D. B. (2011) · Bone · doi:10.1016/j.bone.2010.10.159 · Cited by 219
Systematic review and statistical analysis of the integrity of 33 randomized controlled trials
Bolland, M. J., Avenell, A., Gamble, G. D., & Grey, A. (2016) · Neurology · doi:10.1212/wnl.0000000000003387 · Cited by 106
Self-citation
Metadata
- Authors
- Grey, A., Bolland, M. J., Wattie, D., Horne, A., Gamble, G., & Reid, I. R.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2009-02-01
- Volume
- 94
- Issue
- 2
- Pages
- 538-544
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2081378515
- Cited by
- 110
- References
- 5
- FWCI
- 9.74
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Antiresorptive Effects of a Single Dose of Zoledronate Persist for Two Years: A Randomized, Placebo-Controlled Trial in Osteopenic Postmenopausal Women. https://app.cochat.ai/papers/10.1210/jc.2008-2241
- The paper
- Grey, A., Bolland, M. J., Wattie, D., Horne, A., Gamble, G., & Reid, I. R. (2009). The Antiresorptive Effects of a Single Dose of Zoledronate Persist for Two Years: A Randomized, Placebo-Controlled Trial in Osteopenic Postmenopausal Women. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2008-2241
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.